Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, will participate in the upcoming BofA Securities Health Care Conference 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, will participate in the upcoming BofA Securities Health Care Conference 2025. The company's President and CEO Richard J. Daly, along with other management team members, will present at the conference.
The presentation is scheduled for Wednesday, May 14, 2025, at 8:00 am PT at the Encore Hotel in Las Vegas, Nevada. Investors and interested parties can access the webcast through the Investors section of Catalyst's website at www.catalystpharma.com. A replay of the presentation will remain available for at least 14 days following the event.
Catalyst focuses on in-licensing, developing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases.
Positive
- Management team's participation in a major healthcare conference indicates strong institutional investor interest
- Company maintains commercial-stage status with focus on rare disease medicines, a typically high-margin market segment
Negative
- None.
Details
News Market Reaction – CPRX
The recorded move for CPRX in the trading session of this news was +0.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada.
Presentation Details:
Date: Wednesday, May 14, 2025
Time: 8:00 am PT
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 14 days.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.